Implanet announced on Tuesday March 28, 2017 that sales for the fourth quarter ended December 31, 2016 rose 36%. Sales for the quarter were $2.2 million, which is up from $1.7 million reported in the fourth quarter of 2015.
Implanet Posts 36% Fourth Quarter Sales Increase
1 min read Premium comments
Secondary
Implanet, which is headquartered in Bordeaux, France, is a leading medical technology company specializing in vertebral and knee surgical implants. For the full year of 2016, sales were about $7.8 million, up from about $6.7 million in 2015. In 2016 the company also reported a 46% growth in JAZZ implant system sales.
The following table shows the sales details for 2016.
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/03/Implanet_4Q16_Table.jpg?fit=730%2C153&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/03/Implanet_4Q16_Table.jpg?resize=730%2C153&ssl=1" alt="" width="730" height="153">Source: Implanet company documents
According to company CEO Ludovic Lastennet in a press release, 2016 sales growth, which included a 70% increase in the U.S. market, along with a focus on cost control allowed the company to improve the gross margin and operating costs.
Lastennet said, “We are confident in our ability to record further strong growth in JAZZ sales in 2017 by continuing to focus on clinical benefits for the patient making JAZZ technology a benchmark in spine surgery.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.